Clinical Trials Browser

Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00430365 2026-04-06

IFM2005-02

Phase 3 Completed

614 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT01191060 2026-04-06

IFM/DFCI2009

Phase 3 Completed

700 enrolled

Plasma cell

Disease Progression, Neoplasms, Plasma Cell

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3 Completed

416 enrolled 28 charts 2 FDA

Plasma cell

Amyloidosis

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT01241708 2025-09-17

(Mel/MelVel)

Phase 3 Completed

148 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Plasma cell

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT02066454 2025-08-13

MYELAXAT

Phase 3 Completed

108 enrolled

Classical hematologyPlasma cell

Neoplasms, Plasma Cell, Venous Thromboembolism

NCT03941860 2025-05-23

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Phase 3 Completed

1 enrolled 1 chart

Plasma cell

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02076009 2025-05-01

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

569 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT03277105 2025-04-29

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

522 enrolled 26 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT03748953 2025-03-21

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Phase 3 Completed

37 enrolled 19 charts

Plasma cell

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT02181413 2024-11-19

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Phase 3 Completed

656 enrolled 36 charts

Plasma cell

Multiple Myeloma

NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Phase 3 Completed

660 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01091831 2024-11-06

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Phase 3 Completed

389 enrolled

Plasma cell

Multiple Myeloma

NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Phase 3 Completed

52 enrolled 11 charts

Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

NCT03595800 2024-10-04

HaploMUD-RIC

Phase 3 Completed

9 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Plasma cell

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Plasma cell

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT00551928 2024-07-22

MPRvsMEL200

Phase 3 Completed

402 enrolled

Plasma cell

Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Phase 3 Completed

210 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT03952091 2024-07-03

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

289 enrolled

Plasma cell

Multiple Myeloma

NCT03234972 2024-05-29

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

213 enrolled

Plasma cell

Multiple Myeloma

NCT03217812 2024-04-25

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase 3 Completed

220 enrolled

Plasma cell

Multiple Myeloma

NCT02312258 2023-09-21

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Phase 3 Completed

706 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT00049673 2023-09-13

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Phase 3 Completed

332 enrolled 11 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01951885 2023-09-11

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Phase 3 Completed

101 enrolled 28 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT01850524 2023-07-21

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

705 enrolled 30 charts

Plasma cell

Multiple Myeloma

NCT01063179 2023-06-29

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Phase 3 Completed

511 enrolled

Plasma cell

Multiple Myeloma

NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01734928 2023-06-06

OPTIMISMM

Phase 3 Completed

559 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT02726581 2023-03-27

CheckMate 602

Phase 3 Completed

170 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT01564537 2023-03-10

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 3 Completed

722 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT01090089 2023-02-23

DSM XIII

Phase 3 Completed

348 enrolled

Plasma cell

Multiple Myeloma

NCT02609828 2023-02-16

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Phase 3 Completed

156 enrolled 31 charts

Plasma cell

Cancer Pain, Multiple Myeloma

NCT01568866 2022-11-14

ENDEAVOR

Phase 3 Completed

929 enrolled 21 charts

Plasma cell

Multiple Myeloma

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Phase 3 Completed

1,718 enrolled 22 charts

Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell